Connor, Clark & Lunn Investment Management Ltd. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
Connor, Clark & Lunn Investment Management Ltd. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$1,699,080
-50.8%
61,096
-45.7%
0.01%
-56.5%
Q3 2022$3,454,000
+120.3%
112,532
+462.9%
0.02%
+187.5%
Q2 2021$1,568,000
-27.5%
19,993
-47.3%
0.01%
-33.3%
Q1 2021$2,164,000
+31.3%
37,906
+92.6%
0.01%
+20.0%
Q4 2020$1,648,00019,6770.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders